sorafenib has been researched along with encorafenib in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (encorafenib) | Trials (encorafenib) | Recent Studies (post-2010) (encorafenib) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 149 | 21 | 144 |
| Protein | Taxonomy | sorafenib (IC50) | encorafenib (IC50) |
|---|---|---|---|
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0021 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 2.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Abdel-Maksoud, MS; Ammar, UM; Oh, CH | 1 |
| Abdel-Maksoud, MS; Ali, EMH; Ammar, UM; Mersal, KI; Oh, CH; Yoo, KH | 1 |
| Anbar, HS; El-Gamal, MI; Jeon, HR; Kwon, D; Lee, BS; Oh, CH; Tarazi, H | 1 |
1 review(s) available for sorafenib and encorafenib
| Article | Year |
|---|---|
Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Humans; MAP Kinase Signaling System; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; raf Kinases | 2018 |
3 other study(ies) available for sorafenib and encorafenib
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrroles; Structure-Activity Relationship | 2020 |
Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
Topics: Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Dynamics Simulation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quantitative Structure-Activity Relationship; Sorafenib; Sulfonamides; Thiazoles; Vemurafenib | 2020 |